Product Description
Rilpivirine is an orally administered, non-nucleoside reverse transcriptase inhibitor that is a component drug in combination therapy for antiretroviral-naive patients with HIV-1 infection. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22356290/)
Mechanisms of Action: NNRT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Cross Infection | HIV Infections | Cross Infection | HIV Infections | HIV Infections | HIV Infections
Known Adverse Events: Headache Disorders | Depressive Disorder | Depressive Disorder, Major | Suicidality | Headache | Pregnancy Outcomes | Dizziness | Insomnia | Diarrhea
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Botswana, Canada, Chile, France, Germany, India, Ireland, Italy, Japan, Kenya, Korea, Mexico, Netherlands, Puerto Rico, Romania, Russia, South Africa, Spain, Sweden, Switzerland, Thailand, Uganda, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 19
Highest Development Phases
Phase 3: Acquired Immunodeficiency Syndrome|Communicable Diseases|Deficiency Diseases|HIV Infections
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 219700 | P3 |
Unknown Status |
HIV Infections |
2026-08-25 |
|
| NCT05674656 | P2 |
Recruiting |
HIV Infections |
2026-06-01 |
|
| 2024-512889-33-00 | P2 |
Unknown Status |
HIV Infections |
2026-04-30 |
|
| 2022-000829-24 | P2 |
Active, not recruiting |
HIV Infections |
2026-01-25 |